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ABSTRACT

Provided are tris-quatemary ammonium compounds which
are modulators of nociception and pain.
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USE OF TR/S-QUATERNARY AMMONIUM
SALTS AS PAIN MODULATING AGENTS

pro fen) act by inhibition of the cyclo-oxygenase (Cox-1 ,2)
enzyme. They are especially useful in nociceptive pain of
inflammatory origin (eg. arthritis). However, the NSAID's
have limited efficacy when compared to the opioids. In addition, NSAID's have significant side effects (renal, gastrointestinal, cardiovascular). The discovery of the Cox-2
selective agents (eg. rofecoxib-Vioxx®; celecoxib-Celebrex®; valdecoxib-Bextra®) which have far less gastrointestinal toxicity, was thought to be an advance in NSAID pharmacology. Nonetheless, these agents still have low efficacy
and evidence is now available linking them to significant
cardiovascular events including stroke and myocardial infarction following chronic use. This has resulted in the
removal of both rofecoxib and valdecoxib from the market.
No suitable agent exists for the treatment of neuropathic pain.
GABA-pentin (Neurontin®), an anticonvulsant, has found
use for some neuropathic pain syndromes (eg. diabetic
peripheral neuropathy, postherpetic neuralgia), but it still has
limited efficacy. Duloxetine (Cymbalta®), an antidepressant,
has recently been approved for the treatment of diabetic
peripheral neuropathy. However, it has limited efficacy and
usefulness for other neuropathic pain states. TheN-methyld-aspartate (NMDA) receptor antagonists (eg. ketamine)
have been proposed for the treatment of neuropathic pain.
Their general use is impractical given the marked side effects
including sedation, psychosis and motor impairment. The
limitations of the currently available therapies clearly demonstrate the need for a broad spectrum new class of efficacious and safe analgesic drugs for the treatment of nociceptive and neuropathic pain.
Given the need for more effective, less toxic, analgesic
drugs, a great deal of emphasis has been placed on identifying
novel molecular targets that could form the basis for new
analgesics.

FIELD OF THE INVENTION
The invention relates to the use of tris-quatemary ammonium salts for pain modulation.
BACKGROUND OF THE INVENTION
The treatment of pain is a critical health issue. Acute (eg.
postoperative pain) and chronic (eg. arthritis, low back, cancer) pain affects tens of millions of people annually in the US.
Each year some 30 million people visit a physician with a
complaint of a painful condition. Some 10% of these patients
are seen with chronic pain as their main complaint. The financialloss due to pain has been estimated to exceed 100 billion
dollars a year as a result of medical fees, decreased productivity, litigation and the cost of drugs. New therapeutic agents
with greater efficacy, in particular for chronic neuropathic
pain syndromes (eg. complex regional pain syndrome), and
with fewer side effects would result in significant societal
benefit.
Pain can be broadly divided into two categories: nociceptive and neuropathic pain. Nociceptive pain occurs as a result
of activation of peripheral nociceptors, actually free nerve
endings by noxious stimuli (heat, pressure, inflannnatory
mediators). Examples of nociceptive pain include postsurgical pain, inflammatory pain (eg. arthritis) and low back pain.
Such a pain is often described as "a constant, dull, aching
pain". Neuropathic pain occurs as a result of damage to the
peripheral or central nervous system. Examples of neuropathic pain include radiculopathy (eg. disc impingement on a
nerve), complex regional pain syndrome (CRPS I, II), diabetic peripheral neuropathy or central pain (stroke, spinal
cord injury, multiple sclerosis). Patients typically describe
neuropathic pain as "burning and tingling" in nature. It is
characterized by hyperalgesia (increased painful response to
a noxious stimulus) and allodynia (pain to a previously nonnoxious stimulus).
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SUMMARY OF INVENTION
In one embodiment, compounds corresponding to the following structure are provided.
(I)

In many patients, in particular those with chronic pain
conditions of malignant (cancer-related pain) and non-malignant (arthritis, low back pain, CRPS) origin, pain is inadequately managed with currently available drugs. Available
drugs are simple modifications (eg. extended release) of
drugs from classes which have been available for decades
including the opioids, nonsteroidal anti-inflammatory agents
(NSAID's) or various adjuvants (antidepressants, anticonvulsants) initially approved for other uses besides pain. Opioids
(eg. morphine, oxycodone) are often successfully used for the
treatment of moderate to severe nociceptive pain. Chronic
neuropathic pain is much less responsive to opioids. Use of
opioid analgesics is associated with a broad range of significant side effects including cognitive impairment, respiratory
depression and constipation. In addition, long-term opioid
dosing results in the development of tolerance to the analgesic
effect, drug abuse and dependence. The NSAID's (eg. ibu-
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The three side chains attached to the phenyl ring can be
connected to the 1, 2, and3 positions; the 1, 2, and4 positions;
or the 1, 3 and 5 positions of the phenyl ring.
The values for m1, m2 and m3 are each independently 0, 1,
2, 3, 4 or 5.
The values for n1, n2, and n3 are each independently 1, 2,
3, 4 or 5.
X 18, X 28 , and X 38 are each independently an organic or
inorganic anion.
L 1 , L 2 and L3 are each independently chosen from the
group consisting of ---CH 2 ---CH 2 - , cis -CH=CH-,
trans
---CH=CH-,
-C C-,
---CH 2 -S-,
-S-CH 2 - , -Se-CH 2 - , ---CH 2 -Se-, ---CH 2 ---0-,
---O-CH 2 - , -CH 2 -NH-, -NH---CH 2 - , ---CH 2 NR- where R is a branched or straight chain alkyl group of
one to four carbons, -NR---CH 2 - where R is a branched or
straight chain alkyl group of one to four carbons,
---CH=N-,-N=CH-,and-N N-.
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R 1 , R 2 , and R 3 are each independently five or six membered
nitrogen containing rings as shown in formulas (IIA) and
(liB).

alkylaryl; substituted alkylaryl; arylalkyl; substituted arylalkyl; arylalkenyl; substituted arylalkenyl; arylalkynyl; substituted arylalkynyl; heterocyclic; substituted heterocyclic;
halo; cyano; nitro; SOY 1 , S0 2 Y 1 , S0 2 0Y 1 or S0 2 NHY 1 ,
where Y 1 is selected from hydrogen, lower alkyl, alkenyl,
alkynyl or aryl, and where Y 1 is not hydrogen in SOY 1 and if
Y 1 is alkenyl or alkynyl, the site ofunsaturation is not conjugated with a heteroatom; COY2 , where Y 2 is selected from
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substitutedarylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and where ifY2 comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the carbonyl group; OY3 , where Y 3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY3 comprises alkenyl or alkynyl, the site of unsaturation is not conjugated with
the oxygen; NY4 Ys, where Y 4 and ys are each independently
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY4 or ys comprises
alkenyl or alkynyl, the site ofunsaturation is not conjugated
with the nitrogen; SY 6 , where Y 6 is selected from hydrogen,
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or
substituted heterocyclic, and where ifY 6 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated with the
sulfur; or R4 and Rs together with A 1 and A 2 , or Rs and R 6
togetherwithA2 andA3 , or R 1 s andR 16 togetherwithA 6 and
A 7 , or R 16 and R 17 together with A 7 and A 8 independently
form a three to eight member cyclolkane, substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted
aryl, heterocycle with one to three hetero atoms in the ring, or
substituted heterocycle with one to three hetero atoms in the
ring.
In another embodiment, describes tris-quaternary ammonium compounds as described above which are modulators of
nociception and pain.
In another embodiment, a composition is provided comprising a pharmaceutically acceptable carrier and a compound as described above.
In another embodiment, a method is provided for preventing and/or treating nociception and pain and associated disorders comprising administering a therapeutically effective
amount of a compound as described above to a mammalian
subject in need thereof.
Other methods, features and advantages of the present
invention will be or become apparent to one with skill in the
art upon examination of the following detailed descriptions. It
is intended that all such additional methods, features and
advantages be included within this description, be within the
scope of the present invention, and be protected by the accomparrying claims.

(IIA)

10

(liB)

15

20

A 1 is carbon or nitrogen, provided that when A 1 joins a ring
atom with an unsaturated bond or is a nitrogen, R 9 is absent,
and when A 1 joins a ring atom an unsaturated bond and is a
nitrogen, both R4 and R 9 are absent.
A 2 is carbon or nitrogen, provided that when A 2 joins a ring
atom an unsaturated bond or is a nitrogen, R 10 is absent, and
when A 2 joins a ring atom an unsaturated bond and is a
nitrogen, both Rs and R 10 are absent.
A 3 is carbon or nitrogen, provided that whenA3 joins a ring
atom an unsaturated bond or is a nitrogen, R 11 is absent, and
when A 3 joins a ring atom an unsaturated bond and is a
nitrogen, both R 6 and R 11 are absent.
A 4 is carbon or nitrogen, provided that when A 4 joins a ring
atom an unsaturated bond or is a nitrogen, R 12 is absent, and
when A 4 joins a ring atom an unsaturated bond and is a
nitrogen, both R 7 and R 12 are absent.
As is carbon or nitrogen, provided thatwhenAs joins a ring
atom an unsaturated bond or is a nitrogen, R 13 is absent, and
when As joins a ring atom an unsaturated bond and is a
nitrogen, both R 8 and R 13 are absent.
A 6 is carbon or nitrogen, provided that when A 6 joins a ring
atom an unsaturated bond or is a nitrogen, R 19 is absent, and
when A 6 joins a ring atom an unsaturated bond and is a
nitrogen, both R Is and R 19 are absent.
A 7 is carbon or nitrogen, provided that when A 7 joins a ring
atom an unsaturated bond or is a nitrogen, R 20 is absent, and
when A 7 joins a ring atom an unsaturated bond and is a
nitrogen, both R 16 and R 20 are absent.
A 8 is carbon or nitrogen, provided that when A 8 joins a ring
atom an unsaturated bond or is a nitrogen, R 21 is absent, and
when A 8 joins a ring atom an unsaturated bond and is a
nitrogen, bothR 17 andR21 are absent.
A 9 is carbon or nitrogen, provided that whenA9 joins a ring
atom an unsaturated bond or is a nitrogen, R 22 is absent, and
when A 9 joins a ring atom an unsaturated bond and is a
nitrogen, both R 18 and R 22 are absent.
R 14 or R 23 is absent when any of the bonds to the ammonium nitrogen is unsaturated, and R 14 orR23 is a straight chain
or branched alkyl group of four carbons or fewer when all of
the bonds to the ammonium nitrogen are saturated.
R4 , Rs, R 6 , R 7 , R 8 , R9 , R 10 , R 11 , R 12 , andR 13 orR 1 s, R 16 ,
R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 , when present, are each
independently selected from hydrogen; alkyl; substituted
alkyl; cycloalkyl; substituted cycloalkyl; alkenyl; substituted
alkenyl; alkynyl; substituted alkynyl; aryl; substituted aryl;
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The term "alkylaryl" refers to alkyl-substituted aryl
groups, and "substituted alkylaryl" refers to alkylaryl groups
FIG. 1 shows the time curve of the effect of G Z-5 5 6A in the
further bearing one or more substituents as set forth above.
Rodent Formalin Tonic Pain model following intraperitoneal
The term "arylalkyl" refers to aryl-substituted alkyl
administration. Data are mean±SEM, n=3.
groups, and "substituted arylalkyl" refers to arylalkyl groups
FIG. 2 shows the dose response of the effectofGZ-556Ain
further bearing one or more substituents as set forth above.
Phase 1 and 2 of the Rodent Formalin Tonic Pain model
The term "arylalkenyl" refers to aryl-substituted alkenyl
following intraperitoneal administration. Data are
groups, and "substituted arylalkenyl" refers to arylalkenyl
mean±SEM, n=3.
groups further bearing one or more substituents as set forth
Before the present compositions and methods are 10
above.
described, it is to be understood that the invention is not
The term "arylalkynyl" refers to aryl-substituted alkynyl
limited to the particular methodologies, protocols, assays,
groups, and "substituted arylalkynyl" refers to arylalkynyl
and reagents described, as these can vary. It is also to be
groups further bearing one or more substituents as set forth
understood that the terminology used herein is intended to
above.
describe particular embodiments of the present invention, and 15
The term "heterocyclic" refers to cyclic moieties containis in no way intended to limit the scope of the present invening one or more heteroatoms as part of the ring structure and
tion as set forth in the appended claims.
having 3 to 24 carbon atoms, and "substituted heterocyclic"
It must be noted that as used herein and in the appended
refers to heterocyclic moieties further bearing one or more
claims, the singular forms "a," "an," and "the" include plural
substituents as set forth above.
references unless the context clearly dictates otherwise.
20
The term "acyl" refers to alkyl-carbonyl groups, and "subUnless defined otherwise, all technical and scientific terms
stituted acyl" refers to acyl groups further bearing one or
used herein have the same meanings as commonly undermore substituents as set forth above.
stood by one of ordinary skill in the art to which this invention
The term "halogen" refers to fluoride, chloride, bromide or
belongs. All publications cited herein are incorporated herein
iodide groups.
by reference in their entirety for the purpose of describing and 25
It is understood that in all substituted groups defined above,
disclosing the methodologies, reagents, and tools reported in
polymers arrived at by defining substituents with further subthe publications that might be used in connection with the
stituents to themselves (e.g. substituted aryl having a substiinvention. Nothing herein is to be construed as an admission
tuted aryl group as a substituent which is itself substituted
that the invention is not entitled to antedate such disclosure by
with a substituted aryl group, etc.) are not intended for incluvirtue of prior invention.
30
sion herein. In such cases, the maximum number of such
The term "agonist" refers to a substance which interacts
substituents is three. That is to say that each of the above
with a receptor and increases or prolongs a physiological
definitions is constrained by a limitation that, for example,
response (i.e. activates the receptor).
substituted aryl groups are limited to -substituted aryl-(subThe term "partial agonist" refers to a substance which
stituted aryl)-substituted aryl.
interacts with and activates a receptor to a lesser degree than 35
Compounds of the present invention are tris-quaternary
an agonist.
ammonium salts corresponding to Formula (I):
The term "antagonist" refers to a substance which interacts
with and decreases the extent or duration of a physiological
response of that receptor.
(I)
The terms "disorder," "disease," and "condition" are used 40
inclusively and refer to any status deviating from normal.
The term "lower alkyl" refers to straight or branched chain
alkyl radicals having in the range of 1 to 4 carbon atoms.
The term "alkyl" refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and "substituted alkyl" 45
refers to alkyl radicals further bearing one or more substituThe three side chains attached to the phenyl ring can be
ents including, but not limited to, hydroxy, alkoxy (of a lower
alkyl group), mercapto (of a lower alkyl group), aryl, heteroconnected to the 1, 2, and3 positions; the 1, 2, and4 positions;
or the 1, 3 and 5 positions of the phenyl ring.
cyclic, halogen, trifluoromethyl, cyano, nitro, amino, carThe values for m1, m2 and m3 are each independently 0, 1,
50
boxyl, carbamate, sulfonyl, and sulfonamide.
The term "cycloalkyl" refers to cyclic ring-containing moi2, 3, 4 or 5.
eties containing 3 to 8 carbon atoms, and "substituted
The values for n1, n2, and n3 are each independently 1, 2,
cycloalkyl" refers to cycloalkyl moieties further bearing one
3, 4 or 5.
or more substituents as set forth above.
X 18, X 28 , and X 38 are each independently an organic or
The term "alkenyl" refers to straight or branched chain 55 inorganic anion.
hydrocarbyl groups having at least one carbon-carbon double
U, L 2 and L 3 are each independently chosen from the
bond and having 2 to 19 carbon atoms, and "substituted
group consisting of ---CH 2 ---CH 2 - , cis -CH=CH-,
trans
---CH=CH-,
-C C-,
---CH 2 -S-,
alkenyl" refers to alkenyl groups further bearing one or more
-S-CH 2 - , -Se-CH 2 - , ---CH 2 -Se-, ---CH 2 ---0-,
substituents as set forth above.
The term "alkynyl" refers to straight or branched chain 60 ---O-CH 2 - , -CH 2 -NH-, -NH---CH 2 - , ---CH 2 hydrocarbyl moieties having at least one carbon-carbon triple
NR- where R is a branched or straight chain alkyl group of
one to four carbons, -NR---CH 2 - where R is a branched or
bond and having 2 to 19 carbon atoms, and "substituted
straight chain alkyl group of one to four carbons,
alkynyl" refers to alkynyl moieties further bearing one or
more substituents as set forth above.
---CH=N-,-N=CH-,and-N N-.
R 1 , R 2 , and R 3 are each independently five or six membered
The term "aryl" refers to aromatic groups having 6 to 24 65
carbon atoms, and "substituted aryl" refers to aryl groups
nitrogen containing rings as shown in formulas (IIA) and
further bearing one or more substituents as set forth above.
(liB).
BRIEF DESCRIPTION OF THE DRAWINGS
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A 1 is carbon or nitrogen, provided that when A 1 joins a ring
atom with an unsaturated bond or is a nitrogen, R9 is absent,
and when A 1 joins a ring atom with an unsaturated bond and
is a nitrogen, both R4 and R9 are absent.
A 2 is carbon or nitrogen, provided that when A 2 joins a ring
atom with an unsaturated bond or is a nitrogen, RIO is absent,
and when A 2 joins a ring atom with an unsaturated bond and
is a nitrogen, both Rs and RIO are absent.
A 3 is carbon or nitrogen, provided that whenA3 joins a ring
atom with an unsaturated bond or is a nitrogen, R 11 is absent,
and when A 3 joins a ring atom with an unsaturated bond and
is a nitrogen, both R 6 and R 11 are absent.
A 4 is carbon or nitrogen, provided that when A 4 joins a ring
atom with an unsaturated bond or is a nitrogen, R 12 is absent,
and when A 4 joins a ring atom with an unsaturated bond and
is a nitrogen, both R7 and R 12 are absent.
As is carbon or nitrogen, provided thatwhenAs joins a ring
atom with an unsaturated bond or is a nitrogen, R 13 is absent,
and when As joins a ring atom with an unsaturated bond and
is a nitrogen, both R 8 and R 13 are absent.
A 6 is carbon or nitrogen, provided that when A 6 joins a ring
atom with an unsaturated bond or is a nitrogen, R 19 is absent,
and when A 6 joins a ring atom with an unsaturated bond and
is a nitrogen, both R 1 s and R 19 are absent.
A 7 is carbon or nitrogen, provided that when A 7 joins a ring
atom with an unsaturated bond or is a nitrogen, R 20 is absent,
and when A 7 joins a ring atom with an unsaturated bond and
is a nitrogen, both R 16 and R 20 are absent.
A 8 is carbon or nitrogen, provided that when A 8 joins a ring
atom with an unsaturated bond or is a nitrogen, R 21 is absent,
and when A 8 joins a ring atom with an unsaturated bond and
is a nitrogen, both R 17 and R 21 are absent.
A 9 is carbon or nitrogen, provided that whenA9 joins a ring
atom with an unsaturated bond or is a nitrogen, R 22 is absent,
and when A 9 joins a ring atom with an unsaturated bond and
is a nitrogen, both R 18 and R 22 are absent.
R 14 or R 23 is absent when any of the bonds to the ammonium nitrogen is unsaturated, and R 14 orR23 is a straight chain
or branched alkyl group of four carbons or fewer when all of
the bonds to the ammonium nitrogen are saturated.
R4 Rs, R 6 , R7 , R 8 , R9 , RIO, R 11 , R 12 , and R 13 or R 1 s, R 16 ,
R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 , when present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, SOY 1 , S0 2 Y 1 , S0 2 0Y 1 or S0 2 NHY 1 ,

where Y 1 is selected from hydrogen, lower alkyl, alkenyl,
alkynyl or aryl, and where Y 1 is not hydrogen in SOY 1 and if
Y 1 is alkenyl or alkynyl, the site ofunsaturation is not conjugated with a heteroatom; COY2 , where Y 2 is selected from
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substitutedarylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and where ifY2 comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the carbonyl group; OY3 , where Y 3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY3 comprises alkenyl or alkynyl, the site of unsaturation is not conjugated with
the oxygen; NY4 Ys, where Y 4 and ys are each independently
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY4 or ys comprises
alkenyl or alkynyl, the site ofunsaturation is not conjugated
with the nitrogen; SY 6 , where Y 6 is selected from hydrogen,
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or
substituted heterocyclic, and where ifY 6 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated with the
sulfur; or R4 and Rs together with A 1 and A 2 , or Rs and R 6
togetherwithA2 andA3 , or R 1 s andR 16 togetherwithA 6 and
A 7 , or R 16 and R 17 together withA7 andA 8 independently
form a three to eight member cyclolkane, substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted
aryl, heterocycle with one to three hetero atoms in the ring, or
substituted heterocycle with one to three hetero atoms in the
ring.
For example, R 1 , R 2 , and R3 include pyrrole, pyrrolidine,
pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine,
piperidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, pyrazine, piperazine, pyridazine, and
triazine.
As another example, R4 Rs, R 6 , R7 , R 8 , R9 , RIO, R 11 , R 12 ,
and R 13 or R 1 s, R 16 , R 17 , R 18 , R 19 , R 20 , and R 22 , include
hydrogen, methyl, ethyl, propyl, butyl, trifluoromethyl, pyrrolidine, N-alkyl pyrrolidine (for example where the alkyl
chain is methyl, ethyl or propyl), unsaturated pyrrolidine,
unsaturated N-alkyl pyrrolidine (for example where the alkyl
chain is methyl, ethyl or propyl), aziridine, N-methyl aziridine, azetidine, N-methyl azetidine, unsaturated azetidine,
unsaturated N -methyl azetidine, piperidine, N -methyl pi peridine, unsaturated piperidine, unsaturated N-methyl piperidine, azepane, N-methyl azepane, unsaturated azepane,
unsaturated N-methyl azepane, azocane, N-methyl azocane,
unsaturated azocane, unsaturated N-methyl azocane, 1-azabicyclo[3.2.1]octane, 1-aza-bicyclo[2.2.1]heptane, 8-methyl-8-aza-bicyclo[3.2.1]octane, 1-aza-tricyclo[3.3.1.1 3 .7]
decane, methyl cycloalkyl, methyl substituted cycloalkyl,
methylpyrrolidine, methyl N-alkyl pyrrolidine (for example
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where the alkyl chain is methyl, ethyl or propyl), methyl
unsaturated pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for example where the alkyl chain is methyl, ethyl or
propyl), methyl aziridine, methyl N-methyl aziridine, methyl
azetidine, methyl N-methyl azetidine, methyl unsaturated
azetidine, methyl unsaturated N-methyl azetidine, methyl
piperidine, methyl N-methyl piperidine, methyl unsaturated
piperidine, methyl unsaturated N-methyl piperidine, methyl
azepane, methyl N-methyl azepane, methyl unsaturated
azepane, methyl unsaturated N-methyl azepane, methyl azocane, methy IN-methy I azocane, methy I unsaturated azocane,
methyl unsaturatedN-methyl azocane, methyl-1-aza-bicyclo
[3.2.1]octane, methyl-1-aza-bicyclo[2.2.1]heptane, 8-methyl-8-aza-bicyclo[3.2.1]octane, and methyl-1-aza-tricyclo
[3.3.1.1 3.7]decane.
As a further example, when R4 and R5 togetherwithA 1 and
A 2, or R5 and R 6 together withA2 andA3, or R 15 and R 16
togetherwithA 6 andA7, or R 16 andR 17 togetherwithA7 and
A 8 independently form a three to eight-membered ring, that
ring can be a heterocycle containing up to three hetero atoms
(for example nitrogen, oxygen or sulfur) in the ring, and
further can be substituted with one or more substituents. For
example, possible rings include benzene, pyridine, pyran,
indene, isoindene, benzofuran, isobenzofuran, benzo[b]
thiophene, benzo[ c]thiophene, indole, indolenine, isoindole,
cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, indazole,
indoxazine, benzoxazole, anthranil naphthalene, tetralin,
decalin, chromene, coumarin, chroman-4-one, isocoumarin,
isochromen-3-one, quinoline, isoquinoline, cinnoline,
quinazoline, naphthyrdine, pyrido[3,4-b ]-pyridine, pyridol
[3,2-b]pyridine,
pyrido[4,3,-b]-pyridine,
benzoxazine,
anthracene, phenanthrene, phenalene, fluorene, carazole,
xanthene, acnidine, octahydro-[1]pyridine, 1-methyloctahydro-[1]pyridine, octahydroindole, 1-methyloctahydro-indole, octahydro-cyclopenta[b]pyrrole, 1-methyloctahydrocyclopenta[b ]pyrrole,
decahydroquinoline,
and
1-methyldecahydroquinoline.
18 28
38
X , X , and X ' for example,
2 include F-, c!-, Br-, I-,
N02-, HS04-, S04-, HP04-, P04 -, methanesulfonate, trifluoromethane sulfate, p-toluenesulfonate, benzenesulfonate,
salicylate, proprionate, ascorbate, aspartate, fumarate, galactarate, maleate, citrate, glutamate, glycolate, lactate, malate,
maleate, tartrate, oxalate, succinate, or similar pharmaceutically acceptable organic acid addition salts, including the
pharmaceutically acceptable salts listed in the Journal of
Pharmaceutical Sciences volume 66, page 2, 1977, which are
hereby incorporated by reference. The above salt forms can
be in some cases hydrates or solvates with alcohols and other
solvents.
In a compound of Formula (I), preferably the phenyl ring is
substituted at the 1, 3 and 5 positions.
In a compound of Formula (I), preferably A 1, A 2, A 3, A4,
andA5 are carbon.
In a compound of Formula (I), preferably R 1, R2, and R3
are substituted, six-membered, aromatic rings. More preferably, R\ R2, and R3 are substituted pyridinium rings.
In a compound of Formula (I), preferably R4 is hydrogen,
alkyl, or forms an aryl ring withA 1, A 2 and R5. More preferably, R4 is hydrogen, methyl or forms a phenyl group with A 1,
A 2 andR5.
In a compound of Formula (I), preferably R5 is hydrogen,
alkyl, phenyl, 1-methyl-2-pyrrolidinyl, forms a six-membered ring withA 1,A2 and R4, or forms an aryl ring withA2,
A 3 and R6. More preferably, R5 is hydrogen, methyl, butyl,
phenyl, 1-methyl-2-pyrrolidinyl, forms a phenyl group with
A 1, A 2 and R4, or forms a phenyl group withA2, A 3 and R 6.

35

In a compound of Formula (I), preferably R 6 is hydrogen,
alkyl, or forms an aryl ring withA2, A 3 and R5. More preferably, R 6 ishydrogen,methylorformsa phenyl groupwithA2,
A 3 and R5.
In a compound ofFormula (I), preferably R7 is hydrogen or
alkyl. More preferably, R7 is hydrogen or methyl.
In a compound of Formula (I), preferably R 8 is hydrogen.
In a compound of Formula (I), preferably m=O.
In a compound of Formula (I), preferably n=3.
In a compound of Formula (I), preferably L 1, L 2 and L3 are
---CH 2---CH 2- or -C===C-.
In a compound of Formula (I), preferably X 18 , X 2 8 , and
38
X are halogens. More preferably, X 18 , X 28 , and X 38 are
bromide.
In one embodiment, the compound of Formula (I) is
defined wherein the phenyl ring is 1,3,5 substituted; wherein
m=O;whereinn=3;whereinLis-CH 2CH 2-or---C C-;
wherein R\ R2, and R3 are pyridinium rings; wherein R4 is
hydrogen,methylorformsaphenylgroupwithA 1,A2 andR5;
wherein R5 is hydrogen, methyl, phenyl, butyl, 1-methyl-2pyrrolidinyl, forms a phenyl group with A\ A 2 and R4, or
forms a phenyl group with A 2, A 3 and R 6; wherein R 6 is
hydrogen,methylorformsaphenylgroupwithA2,A3 andR5;
and wherein X\ X 2, and X 3 are Br.
In another embodiment, the compound of Formula (I) is
defined wherein the phenyl ring is 1,3,5 substituted; wherein
m=O; wherein n=3; wherein L is -CH 2CH 2-; wherein R 1,
R2, and R3 are pyridinium rings; wherein R4 is hydrogen,
methyl or forms a phenyl group with A 1, A2 and Rs; wherein
Rs is hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidinyl, forms a phenyl group with A\ A2 and R4, or forms a
phenyl group with A2, A3 and R6; wherein R6 is hydrogen,
methyl or forms a phenyl group with A2, A3 and Rs; and
whereinXl, X2, andX3 are Br.

40

In another embodiment, the compound of Formula (I) is
defined wherein the phenyl ring is 1,3,5 substituted; wherein
m=O; wherein n=3; wherein L is ---C C-; wherein R 1, R2,
and R3 are pyridinium rings; wherein R4 is hydrogen, methyl
or forms a phenyl group withAl, A2 and Rs; wherein Rs is

45

hydrogen, methyl, phenyl, butyl,
1-methyl-2-pyrrolidinyl,
forms a phenyl group withA 1, A 2 and R4, or forms a phenyl
group with A 2' A3 and R 6; wherein R6 is hydrogen, methyl or
2
formsaphenylgroupwithA 2,A3 andR5;andwhereinX 1,X,
and X3 are Br.
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The compounds of the present invention can contain one or
more stereocenters. The invention includes all possible diastereomers and all enantiomeric forms as well as racemic
mixtures. The compounds can be separated into substantially
optically pure compounds.
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Central nervous system disorders which can be treated
according to the method of the present invention include
disorders of nociception, and pain.
In yet another embodiment, the present invention is
directed to a method for preventing pain, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound of Formula (I). In
such a method, the compound of Formula (I) can reduce a
pain response.
The compounds of the present invention can be delivered
directly or in pharmaceutical compositions along with suitable carriers or excipients, as is well known in the art. For
example, a pharmaceutical composition of the invention can
include a conventional additive, such as a stabilizer, buffer,
salt, preservative, filler, flavor enancer and the like, as known
to those skilled in the art. Exemplary buffers include phosphates, carbonates, citrates and the like. Exemplary preservatives include EDTA, EGTA, BHA, BHT and the like.
An effective amount of such agents can readily be determined by routine experimentation, as can the most effective
and convenient route of administration and the most appropriate formulation. Various formulations and drug delivery
systems are available in the art. See, e.g., Gennaro, A. R., ed.
(1995) Remington's Pharmaceutical Sciences.
Suitable routes of administration can, for example, include
oral, rectal, transmucosal, nasal, or intestinal administration
and parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct
intraventricular, intravenous, intraperitoneal, intranasal, or
intraocular injections. In addition, the agent or composition
thereof can be administered sub lingually or via a spray. The
agent or composition thereof can be administered in a local
rather than a systemic manner. For example, a suitable agent
can be delivered via injection or in a targeted drug delivery
system, such as a depot or sustained release formulation.
The pharmaceutical compositions of the present invention
can be manufactured by any of the methods well-known in the
art, such as by conventional mixing, dissolving, granulating,
dragee-making, levigating, emulsifying, encapsulating,
entrapping, or lyophilizing processes. As noted above, the
compositions of the present invention can include one or
more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of administration chosen. For injection, for example, the composition
can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. Fortransmucosal
or nasal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants
are generally known in the art. In a preferred embodiment of
the present invention, the present compounds are prepared in
a formulation intended for oral administration. For oral
administration, the compounds can be formulated readily by
combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable
the compounds of the invention to be formulated as tablets,
pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject. The compounds can also be formulated in rectal compositions such as
suppositories or retention enemas, e.g., containing conventiona! suppository bases such as cocoa butter or other glycerides.

Pharmaceutical preparations for oral use can be obtained as
solid excipients, optionally grinding a resulting mixture, and
processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable
excipients are, in particular, fillers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maize starch, wheat starch, rice starch,
potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents can be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as
sodium alginate. Also, wetting agents such as sodium dodecyl
sulfate can be included.
Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions can be used, which can
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide,
lacquer solutions, and suitable organic solvents or solvent
mixtures. Dyestuffs or pigments can be added to the tablets or
dragee coatings for identification or to characterize different
combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-fit capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as lactose,
binders such as starches, and/or lubricants such as talc or
magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers can be added.
All formulations for oral administration should be in dosages
suitable for such administration.
In one embodiment, the compounds of the present invention can be administered transdermally, such as through a skin
patch, or micro-needle patch, or topically. In one aspect, the
transdermal or topical formulations of the present invention
can additionally comprise one or multiple penetration
enhancers or other effectors, including agents that enhance
migration of the delivered compound. Trans dermal or topical
administration could be preferred, for example, in situations
in which location specific delivery is desired.
For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered
in the form of an aerosol spray presentation from pressurized
packs or a nebulizer, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or any other suitable gas.
In the case of a pressurized aerosol, the appropriate dosage
unit can be determined by providing a valve to deliver a
metered amount. Capsules and cartridges of, for example,
gelatin, for use in an inhaler or insufflator can be formulated.
These typically contain a powder mix of the compound and a
suitable powder base such as lactose or starch.
Compositions formulated for parenteral administration by
injection, e.g., by bolus injection or continuous infusion can
be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Formulations for parenteral administration
include aqueous solutions or other compositions in watersoluble form.

10

15

20

25

30

35

40

45

50

55

60

65

US 9,155,733 B2
13

14

Suspensions of the active compounds can also be prepared
as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles include fatty oils such as sesame oil and
synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to
allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient can be in powder form for
constitution with a suitable vehicle, e.g., sterile pyrogen-free
water, before use.
As mentioned above, the compositions of the present
invention can also be formulated as a depot preparation. Such
long acting formulations can be administered by implantation
(for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the present compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable
oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
Suitable carriers for the hydrophobic molecules of the
invention are well known in the art and include co-solvent
systems comprising, for example, benzyl alcohol, a nonpolar
surfactant, a water-miscible organic polymer, and an aqueous
phase. The co-solvent system can be the VPD co-solvent
system. VPD is a solution of3% w/v benzyl alcohol, 8% w/v
of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
The VPD co-solvent system (VPD:5 W) consists of VPD
diluted 1:1 with a 5% dextrose in water solution. This cosolvent system is effective in dissolving hydrophobic compounds and produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system can be
varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components can be varied. For example, other lowtoxicity nonpolar surfactants can be used instead of
polysorbate 80, the fraction size of polyethylene glycol can be
varied, other biocompatible polymers can replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or
polysaccharides can substitute for dextrose.
Alternatively, other delivery systems for hydrophobic molecules can be employed. Liposomes and emulsions are well
known examples of delivery vehicles or carriers for hydrophobic drugs. Liposomal delivery systems are discussed
above in the context of gene-delivery systems. Certain
organic solvents such as dimethylsulfoxide also can be
employed, although usually at the cost of greater toxicity.
Additionally, the compounds can be delivered using sustained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustainedrelease materials are established and available to those of skill
in the art. Sustained-release capsules can, depending on their
chemical nature, release the compounds for a few weeks up to
over 100 days. Depending on the chemical nature and the
biological stability of the therapeutic reagent, additional
strategies for stabilization can be employed.
For any composition used in the present methods of treatment, a therapeutically effective dose can be estimated initially using a variety of techniques well known in the art.
Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms.

Toxicity and therapeutic efficacy of such molecules can be
determined by standard pharmaceutical procedures in cell
cultures or experimental animals, e.g., by determining the
LD 50 (the dose lethal to 50% of the population) and the ED 5 0
(the dose therapeutically effective in 50% of the population).
The dose ratio of toxic to therapeutic effects is the therapeutic
index, which can be expressed as the ratio LD 50/ED 50 . Agents
that exhibit high therapeutic indices are preferred.
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Dosages preferably fall within a range of circulating concentrations that includes the ED 50 with little or no toxicity.
Dosages can vary within this range depending upon the dosage form employed and the route of administration utilized.
The exact formulation, route of administration, and dosage
should be chosen, according to methods known in the art, in
view of the specifics of a subject's condition.
The amount of agent or composition administered will, of
course, be dependent on a variety of factors, including the sex,
age, and weight of the subject being treated, the severity of the
affliction, the mauner of administration, and the judgment of
the prescribing physician.
The present compositions can, if desired, be presented in a
pack or dispenser device containing one or more unit dosage
forms containing the active ingredient. Such a pack or device
can, for example, comprise metal or plastic foil, such as a
blister pack. The pack or dispenser device can be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier can also be prepared, placed in an
appropriate container, and labeled for treatment of an indicated condition.
These and other embodiments of the present invention will
readily occur to those of ordinary skill in the art in view of the
disclosure herein, and are specifically contemplated.
EXAMPLES
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The invention is further understood by reference to the
following example, which is intended to be purely exemplary
of the invention. The present invention is not limited in scope
by the exemplified embodiment, which is intended as an
illustration of a single aspect of the invention only. Any methods that are functionally equivalent are within the scope of the
invention. Various modifications of the invention in addition
to those described herein will become apparent to those
skilled in the art from the foregoing description. Such modifications fall within the scope of the appended claims.
Example 1
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Preparation of
1,3,5-tris-(5-hydroxypent-1-ynyl)-benzene
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-continued

1,3,5-tris-(5-hydroxy-1-pentynyl)benzene (2.84 g, 8.6
mmol) was dissolved in methanol (30 mL) and 10% Pd!C (5%
w/w) was added. The resulting mixture was hydrogenated on
a Parr hydrogenation apparatus (45 psi) for 4 hours. The
catalyst was removed by filtration through a celite pad. The
filter cake was rinsed with methanol, and the combined
organic liquors were concentrated under reduced pressure.
The crude product was purified by colunm chromatography
(CHCI 3 :MeOH 6:1) to afford 2.84 g of 1,3,5-tris-(5-hydroxypentyl)benzene. Yield 96%. 1 H NMR (300 MHz, CDCI 3 ) o
6.81 (s, 3H), 3.62 (t, 1=6.3 Hz, 6H), 2.57 (t, 1=7.5 Hz, 6H),
1.53-1.70 (m, 12H), 1.38 (m, 6H) ppm; 13 C NMR (75 MHz,
CDCI 3 ) o142.5, 126.1, 63.1, 36.1, 32.9, 31.5, 25.7 ppm.

HO

OH
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OH
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1,3,5-Tribromobenzene (10 g, 31.76 mmol), 4-pentyn-1-ol
(10.69 g, 127.06 mmol) and bis(triphenylphosphine)palladium(II) dichloride were stirred in triethylamine under nitro-

Example 3
20

gen for 5 minutes. Copper(!) iodide (92 mg, 0.48 mmol) was
added and the mixture was stirred for 6 hours at 80° C. The
mixture was cooled to room temperature, filtered through a
celite pad and rinsed with ethyl acetate. The combined filtrate

Preparation of 1,3,5-tris-(5-bromopentyl)benzene

25

HO

was evaporated to dryness under reduced pressure. The

OH

resulting residue was purified by column chromatography
(CHCI 3 :MeOH 10:1) to afford 7.61 g of 1,3,5-tris-(5-hydroxy-1-pentynyl)benzene. Yield: 74%. 1 H NMR (300 MHz,

30

CDCI 3 ) o7.31 (3, 3 h), 3.81 (t, 1=6.0 Hz, 6H), 2.52 (t, 1=6.9
Hz, 6H), 1.85 (m, 6H);

13

C NMR (7 5 MHz, CDCI 3 ) o 133 .8,

124.2, 90.5, 80.0, 61.9, 31.5, 16.2 ppm.
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Preparation of 1,3,5-tris-(5-hydroxypentyl)benzene
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1,3,5-tris-(5-hydroxypentyl)benzene (2.83 g, 8.41 mmol)
and carbon tetrabromide (10.99 g, 32.80 mmol) were dissolved in dry methylene chloride (50 mL) and cooled to oo C.
Triphenylphosphine (9.03 g, 34.33 mmol) was added dropwise and the mixture was stirred for 30 minutes at oo C. The
mixture was poured into hexanes (250 mL ), filtered through a
short silica gel colunm and washed with ethy I acetatelhexanes
(1/4). The combined organic solvents were evaporated to
dryness under reduced pressure. The resulting residue was
purified by column chromatography (hexanes:ethyl acetate
8:1) to afford 4.08 g of 1,3,5-tris-(5-bromopentyl)-benzene.
Yield 92%. 1 H NMR (300 MHz, CDCI 3 ) o6.81 (s, 3 h), 3.41
(t, 1=6.9 Hz, 6H), 2.60 (t, 1=7.5 Hz, 6H), 1.88 (m, H), 1.45 (m,
6H) ppm; 13 C NMR (75 MHz, CDCI 3 ) o142.4, 126.1, 35.9,
34.2, 32.9, 30.9, 28.2 ppm.
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Example 4

departing from the spirit and scope of the invention. All such
modifications and variations are intended to be included
herein within the scope of this disclosure and the present
invention and protected by the following claims.
What is claimed is:
1. A method for treating neuropathic pain resulting from
damage to the peripheral nervous system, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound of Formula (I):

Preparation of
1,3,5-tris-[ 5-(1-quinolinium)pentyl]benzene
tribromide

Br

Br

10
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C(5
I
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A mixture of 1,3,5-tris-(5-bromopentyl)benzene (251 mg,
0.48 mmol) and quinoline (930 mg, 7.20 mmol) was heated at
60-70° C. for 12 hours. The resultant mixture was washed
with diethyl ether and then dissolved in water (15 mL), the
aqueous solution was washed with diethyl ether (30 mLx5),
then lyophilized to afford 390 mg of 1,3,5-tris-[5-(1-quinolinium)pentyl]-benzene tribromide. Yield 89%. 1 H NMR
(300 MHz, CD 3 0D) o 9.46 (dd, 1=6.0, 1.5 Hz, 3H), 9.22 (d,
1 8.4 Hz, 3H), 8.57 (d, 1=9.0 Hz, 3H), 8.45 (dd, 1=8.4, 1.5 Hz,
3H), 8.30 (m, 3H), 8.02-8.14 (m, 6H), 6.8 (s, 3H), 5.11 (t, 7.5
Hz, 6H), 2.56 (t, 1=7.5 Hz, 6H), 2.14 (m, 6H), 1.69 (m, 6H),
1.52 (m, 6H) ppm; 13 C NMR (75 MHz, CD 3 0D) o 150.3,
148.9, 143.4, 139.4, 137.3, 132.2, 131.8, 131.4, 127.2, 123.1,
119.9, 59.4, 36.7, 32.3, 31.1, 27.3 ppm.

30

35

40

wherein
the three side chains attached to the phenyl ring are connected to the 1, 3 and 5 positions of the phenyl ring;
m1, m2 and m3 are each 0;
n1, n2, and n3 are each 3;
X 18 , X 28 , and X 38 are each independently an organic or
inorganic anion;
L 1 , L 2 and L3 are each -CH 2 -CH 2 - ;
R 1 , R 2 , and R3 are each quinolinium or isoquinolinium and
attached to (CH 2 )nu (CH 2 )n 2 , or (CH 2 )n 3 at the quaternized nitrogen of the quinolinium or isoquinolinium.
2. The method of claim 1, wherein the compound of Formula (I) is 1,3,5-tris-[5-(1-quinolinium)-pentyl]-benzene tribromide.
3. The method of claim 1, wherein the pain is chronic.
4. The method of claim 1, wherein the pain is cancerrelated pain.
5. The method of claim 1, wherein the pain is non-malignant pain.
6. A method for treating inflammatory pain resulting from
activation of peripheral nociceptor, comprising administering
to a mammalian subject in need thereof a therapeutically
effective amount of a compound of Formula (I):

(I)

Example 5
A rat model of tonic inflammatory pain (the formalin test)
was used in this study (Wheeler-Aceta and Cowan, 1991).
Fifty fll offormalin (5%) was injected subcutaneously (SC)
into the dorsal surface of the left hind paw. This procedure
typically produces a biphasic behavioral response consisting
of flinching, lifting and licking. The first phase (0-10 min) is
thought to result from direct stimulation of nociceptors (nociceptive pain) whereas the second phase (20-60 min) is
thought to involve central sensitization. Rats (4-8/dose/treatment) were pretreated 15 min prior to formalin (SC) injection
with GZ-556A (90-180 mg/kg) administered by the IP route.
Saline served as control. Incidences of formalin-induced
flinching were counted continuously in 5 min intervals for 60
min. Each rat received only one treatment. The results are
presented in FIGS. 1 and 2.
It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications can be made without
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wherein
the three side chains attached to the phenyl ring are connected to the 1, 3 and 5 positions of the phenyl ring;
m1, m2 and m3 are each 0;
n1, n2, and n3 are each 3;
X 18 , X 28 , and X 38 are each independently an organic or
inorganic anion;
L 1 , L 2 and L3 are each -CH 2 -CH 2 - ;
R 1 , R 2 , and R3 are each quinolinium or isoquinolinium and
attached to (CH 2 )n 1 . (CH 2 )n 2 , or (CH 2 )n 3 at the quaternized nitrogen of the quinolinium or isoquinolinium.
7. The method of claim 6, wherein the compound of Formula (I) is 1,3,5-tris-[5-(1-quinolinium)-pentyl]-benzene tribromide.
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